[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07721259":3,"trial-entities:NCT07721259":158,"trial-summary:NCT07721259":162},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":23,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":68,"secondary_outcomes":77,"sex":88,"minimum_age":89,"maximum_age":90,"healthy_volunteers":91,"eligibility_criteria":92,"std_ages":130,"locations":133,"central_contacts":152,"overall_officials":154,"references":156,"see_also_links":157},"NCT07721259","RG1126489","A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","A Multiantigen Vaccine (STEMVAC) for Adjuvant Treatment of Patients With Moderate or Extensive Residual Triple-Negative Breast Cancer","NOT_YET_RECRUITING","2030-07-16","2026-07","2026-07-23","2026-09-30","University of Washington","OTHER",true,"This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer disease-free survival compared to other subtypes. While patients who have no remaining tumor in the breast or lymph nodes after surgery have excellent long-term outcomes, patients with moderate or extensive residual cancer burden remain at high risk for early disease return and poorer prognosis. STEMVAC is designed to target proteins that tumor cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Giving STEMVAC after surgery may improve disease-free survival rates in TNBC patients with moderate or extensive residual cancer burden.","OUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM A: Patients receive CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2-polyepitope plasmid deoxyribonucleic acid (DNA) vaccine (STEMVAC) with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) intradermally (ID) every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.\n\nARM B: Patients receive GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.\n\nAfter completion of study treatment, patients are followed up at 3 weeks after their last vaccination and then every 6 months for 3 years.",[19,20,21,22],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma",[],"INTERVENTIONAL","TREATMENT",[27],"PHASE2",{"count":29,"type":30},60,"ESTIMATED",[32,42,58],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":38},"BIOLOGICAL","CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2-polyepitope Plasmid DNA Vaccine","Given ID",[37],"Arm A (STEMVAC, GM-CSF)",[39,40,41],"CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2 Plasmid Vaccine","STEMVAC","STEMVAC Th1 Polyepitope Plasmid-based Vaccine",{"type":43,"name":44,"description":35,"armGroupLabels":45,"otherNames":47},"DRUG","Recombinant Granulocyte-Macrophage Colony-Stimulating Factor",[37,46],"Arm B (GM-CSF)",[48,49,50,51,52,53,54,55,56,57],"Colony-Stimulating Factor, Granulocyte-Macrophage","CSF 39300","CSF 39300\u002FGM-CSF","CSF-GM (Hoechst)","GM CSF","GM-CSF","GM-CSF (Schering)","GMCSF","Recombinanr Colony-Stimulating Factor 2","Recombinant Colony-Stimulating Factor 2",{"type":59,"name":60,"description":61,"armGroupLabels":62,"otherNames":63},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[37,46],[64,65,66,67],"Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection",[69,73],{"measure":70,"description":71,"timeFrame":72},"Invasive breast cancer free survival (IBCFS)","Kaplan-Meier curves will be generated with median estimation and 95% confidence interval, and log-rank tests will be conducted to compare the survival difference between groups. Will calculate the 3-year IBCFS rate with a 95% confidence interval from Kaplan-Meier methods using Greenwood standard errors.","Time from randomization to local or distant recurrence or death, assessed up to 3 years",{"measure":74,"description":75,"timeFrame":76},"Dynamics and characteristics of circulating tumor deoxyribonucleic acid (ctDNA)","Through serial ctDNA evaluation, each sample will be assessed for ctDNA detectability and, if detectable, total ctDNA mass (continuous variable, as reported by the assay platform) will be calculated. ctDNA detectability and quantitative ctDNA measures will be summarized descriptively by timepoint and study arm, and changes over time will be evaluated using methods appropriate to the final endpoint definition, data distribution, and repeated-measures structure of the data. Associations with IBCFS will also be explored. Copy number variants (including aneuploidy, chromosome-level gains, losses, and amplifications, as defined by the final assay methodology) will also be tracked and tabulated, and changes over time will be evaluated descriptively in both study arms.","Up to 3 weeks after last vaccination",[78,81,84],{"measure":79,"description":80,"timeFrame":76},"Incidence of adverse events","Safety and systemic toxicity will be determined by clinical and laboratory parameters evaluated at protocol-specified time points. Toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0. The type and grade of toxicities observed during the immunization regimen will be summarized, and the duration of toxicities will be summarized using descriptive statistics. All adverse events reported by the investigator will be tabulated according to the affected body system. The frequency and severity of adverse events will be summarized using proportions and corresponding 95% confidence intervals. Demographic and baseline characteristics obtained at enrollment will be summarized in tabular and\u002For graphical formats using descriptive statistics.",{"measure":82,"description":83,"timeFrame":76},"Immune response","Immune response to CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2-polyepitope plasmid DNA vaccine (STEMVAC) will be measured in peripheral blood functionally by IFN-g enzyme-linked immunosorbent spot, phenotypically using cytometry by time-of-flight to identify T-cell clonal populations, and genomically, using T-cell receptor beta sequencing of CD4+ CD8+ T-cells.",{"measure":85,"description":86,"timeFrame":87},"Expression of epithelial to mesenchymal transformation (EMT)-associated genes","EMT-associated gene expression profiles in residual triple negative breast cancer in surgical pathology samples will be defined for each patient with particular attention on STEMVAC antigen expression. Expression of these EMT-related genes will be assessed using RNA extracted from formalin-fixed paraffin-embedded tissue.","Archival tissue is collected after enrollment, within 30 days of baseline visit","ALL","18 Years",null,false,{"inclusion":93,"exclusion":113,"raw_text":129},[94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112],"At least 18 years of age","Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2","Triple-negative breast cancer as determined by the treating oncologist","Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist","Patients whose tumors progress on neoadjuvant therapy may be enrolled","No clinical evidence of local or distant recurrence","Plan to receive standard of care adjuvant directed therapy","Completed standard of care locoregional treatment, including definitive breast and lymph node surgery followed by standard radiation therapy, if recommended","Residual cancer burden (RCB) index 2 or 3 as calculated per routine anatomic pathology clinical standards","Absolute neutrophil count (ANC) ≥ 800\u002FμL (within 30 days of first study vaccine administration)","Hemoglobin (Hgb) ≥ 8 g\u002FdL (within 30 days of first study vaccine administration)","Platelets ≥ 75,000\u002F μL (within 30 days of first study vaccine administration)","Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome, in whom total bilirubin must be \\\u003C 3.0 mg\u002FdL (within 30 days of first study vaccine administration)","Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) ≤ 1.5 x institutional ULN (within 30 days of first study vaccine administration)","Creatinine ≤ 1.5 x ULN mg\u002FdL or creatinine clearance \\> 60 mL\u002Fmin (within 30 days of first study vaccine administration)","At least 28 days post systemic steroids prior to enrollment, unless used as part of prophylaxis to prevent intravenous (IV) contrast reactions.","Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed","Must have recovered from major infections and\u002For surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment","Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a person of child-bearing potential. Acceptable methods of contraception are abstinence, condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal",[114,115,116,117,118,119,120,121,122,123,124,125,126,127,128],"Toxicities related to prior exposure to immune checkpoint inhibitors for which immune checkpoint inhibitors cannot be safely continued as determined by study investigator","Germline BRCA1 or BRCA2 mutations with adjuvant olaparib planned within the study period","NOTE: If olaparib is not planned, then these patients are eligible","Any known cardiac conditions:","Symptomatic restrictive cardiomyopathy","Dilated cardiomyopathy","Unstable angina within 4 months prior to enrollment","New York Heart Association functional class III-IV heart failure on active treatment","Symptomatic pericardial effusion","Autoimmune disease requiring active systemic treatment","Known hypersensitivity reaction to the GM-CSF adjuvant; any known contra-indication to GM-CSF","Pregnant or breast feeding","Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \\[HBsAg\\] reactive), or hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] is detected)","Major surgery within the 4 weeks prior to initiation of first study vaccine","Enrollment in any other clinical protocol or investigational trial that involves concurrent administration of experimental therapy and\u002For therapeutic devices, or investigational drug. Patients who completed prior clinical trials (such as neoadjuvant treatment, surgery or radiation trials) and are on long term follow up are permitted","Inclusion Criteria:\n\n* At least 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2\n* Triple-negative breast cancer as determined by the treating oncologist\n* Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist\n* Patients whose tumors progress on neoadjuvant therapy may be enrolled\n* No clinical evidence of local or distant recurrence\n* Plan to receive standard of care adjuvant directed therapy\n* Completed standard of care locoregional treatment, including definitive breast and lymph node surgery followed by standard radiation therapy, if recommended\n* Residual cancer burden (RCB) index 2 or 3 as calculated per routine anatomic pathology clinical standards\n* Absolute neutrophil count (ANC) ≥ 800\u002FμL (within 30 days of first study vaccine administration)\n* Hemoglobin (Hgb) ≥ 8 g\u002FdL (within 30 days of first study vaccine administration)\n* Platelets ≥ 75,000\u002F μL (within 30 days of first study vaccine administration)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome, in whom total bilirubin must be \\\u003C 3.0 mg\u002FdL (within 30 days of first study vaccine administration)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) ≤ 1.5 x institutional ULN (within 30 days of first study vaccine administration)\n* Creatinine ≤ 1.5 x ULN mg\u002FdL or creatinine clearance \\> 60 mL\u002Fmin (within 30 days of first study vaccine administration)\n* At least 28 days post systemic steroids prior to enrollment, unless used as part of prophylaxis to prevent intravenous (IV) contrast reactions.\n\n  * Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed\n* Must have recovered from major infections and\u002For surgical procedures; and in the opinion of the investigator, not have any significant active concurrent medical illnesses or condition precluding protocol treatment\n* Patients of child-bearing potential must agree to use dual methods of contraception and have a negative urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a person of child-bearing potential. Acceptable methods of contraception are abstinence, condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal\n\nExclusion Criteria:\n\n* Toxicities related to prior exposure to immune checkpoint inhibitors for which immune checkpoint inhibitors cannot be safely continued as determined by study investigator\n* Germline BRCA1 or BRCA2 mutations with adjuvant olaparib planned within the study period\n\n  * NOTE: If olaparib is not planned, then these patients are eligible\n* Any known cardiac conditions:\n\n  * Symptomatic restrictive cardiomyopathy\n  * Dilated cardiomyopathy\n  * Unstable angina within 4 months prior to enrollment\n  * New York Heart Association functional class III-IV heart failure on active treatment\n  * Symptomatic pericardial effusion\n* Autoimmune disease requiring active systemic treatment\n* Known hypersensitivity reaction to the GM-CSF adjuvant; any known contra-indication to GM-CSF\n* Pregnant or breast feeding\n* Known history of human immunodeficiency virus (HIV) infection, hepatitis B (e.g., hepatitis B virus surface antigen \\[HBsAg\\] reactive), or hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid \\[RNA\\] is detected)\n* Major surgery within the 4 weeks prior to initiation of first study vaccine\n* Enrollment in any other clinical protocol or investigational trial that involves concurrent administration of experimental therapy and\u002For therapeutic devices, or investigational drug. Patients who completed prior clinical trials (such as neoadjuvant treatment, surgery or radiation trials) and are on long term follow up are permitted",[131,132],"ADULT","OLDER_ADULT",[134],{"facility":135,"city":136,"state":137,"zip":138,"country":139,"contacts":140,"geoPoint":149},"Fred Hutch\u002FUniversity of Washington Cancer Consortium","Seattle","Washington","98109","United States",[141,146],{"name":142,"role":143,"phone":144,"email":145},"Research Coordinator(s)","CONTACT","866-932-8588","cvitrial@uw.edu",{"name":147,"role":148},"Natasha Hunter, MD","PRINCIPAL_INVESTIGATOR",{"lat":150,"lon":151},47.60621,-122.33207,[153],{"name":142,"role":143,"phone":144,"email":145},[155],{"name":147,"affiliation":135,"role":148},[],[],{"nct_id":4,"conditions":159,"biomarkers":161},[160],"Breast Carcinoma",[],{"nct_id":4,"found":15,"summary":163,"prompt_version":173},{"design":164,"status":165,"heading":166,"summary":167,"follow_up":168,"word_count":169,"commitments":170,"compensation":171,"drugs_mentioned":172},"This is an interventional study that plans to enroll 60 participants. Participants will be randomly assigned to one of two groups.","completed","STEMVAC Vaccine for Triple-Negative Breast Cancer","This study is testing a vaccine called STEMVAC (CD105\u002FYb-1\u002FSOX2\u002FCDH3\u002FMDM2-polyepitope Plasmid DNA Vaccine) along with a drug called recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) to see if it can help people with triple-negative breast cancer (TNBC) live longer without their cancer coming back. This is for patients who still have some cancer left after their initial chemotherapy and surgery. The study aims to enroll 60 participants aged 18 or older who have TNBC and a good performance status. Researchers will measure how long patients live without their cancer returning (invasive breast cancer free survival) for up to 3 years, and also look at changes in circulating tumor DNA (ctDNA) after vaccination. The study is currently recruiting.","After treatment, you would be followed up at 3 weeks after your last vaccination and then every 6 months for 3 years.",114,"You would receive injections of the vaccine and\u002For GM-CSF every 3 weeks for 3 doses, followed by two booster injections. You would also have blood samples collected throughout the trial.","Not stated in the trial record.",[34,44],"v2"]